Gene · 1308
Papers3,031
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,031
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CD20+ T follicular helper-like cells drive antigen-specific autoimmunity in bullous pemphigoid. | J Clin Invest | 2026 | 42412554 | PubTator, text mining | PubMed |
| Identification of Biomarkers and Construction of Predictive Models for Sepsis and Septic Shock. | Clin Lab | 2026 | 42411682 | PubTator, text mining | PubMed |
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients. | Acta Derm Venereol | 2026 | 42374764 | PubTator, text mining | PubMed |
| Real-world outcomes of stapokibart-based combination therapy for bullous pemphigoid: a single-centre retrospective cohort. | Clin Exp Dermatol | 2026 | 42370831 | PubTator, text mining | PubMed |
| A Cohort-Based Genetic Analysis of Keratoconus in Turkey Reveals a Substantial Proportion of Novel Variants and Suggests Possible Oligogenic Contributions to Keratoconus. | Genes (Basel) | 2026 | 42353764 | PubTator, text mining | PubMed |
| A Multicenter Analysis of Patients with Bullous Pemphigoid: Clinical Characteristics and Insights into Drug-Associated Disease. | Int J Mol Sci | 2026 | 42353304 | PubTator, text mining | PubMed |
| Mechanistic modeling of FcRn-dependent IgG drug interactions: Clinical applications and dosing implications. | J Pharmacokinet Pharmacodyn | 2026 | 42350716 | PubTator, text mining | PubMed |
| Proteomic analysis of dental enamel from 20 Homo naledi individuals shows no male markers. | Cell | 2026 | 42341758 | PubTator, text mining | PubMed |
| Serum BP180 and BP230 autoantibodies in Alzheimer's disease: diagnostic and cognitive associations in a retrospective study. | Front Aging Neurosci | 2026 | 42311495 | PubTator, text mining | PubMed |
| Collagen XVIIα1 in skin and hair aging: Mechanisms, stem cell niche regulation, and translational strategies. | J Dermatol Sci | 2026 | 42276855 | PubTator, text mining | PubMed |
| Dystrophia Smolandiensis is characterized by a novel NQO1 variant and a distinct phenotype from COL17A1-associated epithelial recurrent erosion dystrophy. | Acta Ophthalmol | 2026 | 42267673 | PubTator, text mining | PubMed |
| Risk of Bias and Reporting Quality in BP180/BP230 ELISA Diagnostic Studies of Bullous Pemphigoid: A Meta-Epidemiological Study. | Int J Dermatol | 2026 | 42265820 | PubTator, text mining | PubMed |
| Integrative transcriptomic and machine learning analysis identifies key extracellular matrix-related genes in diabetic retinopathy. | Sci Rep | 2026 | 42265151 | PubTator, text mining | PubMed |
| Comparative effects of hyaluronic acid-amino acid and polynucleotide mixtures on extracellular matrix gene expression in human dermal fibroblasts. | J Wound Care | 2026 | 42247333 | PubTator, text mining | PubMed |
| The skin as a sentinel organ for neurodegeneration: An underrecognized target for dementia prevention. | Intractable Rare Dis Res | 2026 | 42221048 | PubTator, text mining | PubMed |
| The Role of Anti-BP180 Antibody Monitoring in Bullous Pemphigoid: An Italian Single-Center Experience. | Dermatol Pract Concept | 2026 | 42190186 | PubTator, text mining | PubMed |
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: Evidence from a prospective case-control study supporting ECD-BP180 enzyme-linked immunosorbent assay in reducing diagnostic delay. | J Am Acad Dermatol | 2026 | 42173195 | PubTator, text mining | PubMed |
| Exploring Immune-Related Gene and Mechanisms in Rosacea Through Transcriptome Analysis and Mendelian Randomization. | Biomed Res Int | 2026 | 42112773 | PubTator, text mining | PubMed |
| Stapokibart's clinical effectiveness in treating moderate-to-severe bullous pemphigoid in the elderly. | Front Immunol | 2026 | 42112370 | PubTator, text mining | PubMed |
| HLA genotype, clinical and immunofluorescence findings of 30 patients with type VII collagen antibody positive subepidermal bullous disease. | Clin Exp Dermatol | 2026 | 42101637 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1308/papers?page=2